Editorial: Real World Outcomes of Lymphoma From India.
作者信息
Kumar Lalit, Kn Naresh, Gujral Sumeet, Kulkarni Padmaj, Stockler Martin R, Nair Reena
机构信息
Department of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
出版信息
Front Oncol. 2022 Jul 19;12:922370. doi: 10.3389/fonc.2022.922370. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Real World Outcomes of Lymphoma From India.社论：印度淋巴瘤的真实世界结局
Front Oncol. 2022 Jul 19;12:922370. doi: 10.3389/fonc.2022.922370. eCollection 2022.
2
Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.法国霍奇金淋巴瘤和主要 B 细胞非霍奇金淋巴瘤的真实世界疾病负担。
J Med Econ. 2020 Mar;23(3):235-242. doi: 10.1080/13696998.2019.1702990. Epub 2019 Dec 26.
3
Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.德国肿瘤学家网络中利妥昔单抗生物类似药在非霍奇金淋巴瘤中的真实世界应用和接受情况。
Future Oncol. 2020 May;16(15):1001-1012. doi: 10.2217/fon-2020-0180. Epub 2020 Apr 14.
4
Rituximab biosimilars for lymphoma in Europe.利妥昔单抗生物类似药在欧洲的淋巴瘤治疗中的应用。
Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017.
5
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.美国霍奇金淋巴瘤患者程序性死亡受体-1（PD-1）抑制剂的疗效和毒性：一项真实世界、多中心回顾性分析。
Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19.
6
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.美国弥漫性大 B 细胞淋巴瘤患者的真实世界特征、治疗模式、医疗资源利用和成本
Oncologist. 2021 May;26(5):e817-e826. doi: 10.1002/onco.13721. Epub 2021 Mar 15.
7
Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.不列颠哥伦比亚省弥漫性大 B 细胞淋巴瘤的真实世界成本分析。
Curr Oncol. 2019 Apr;26(2):108-113. doi: 10.3747/co.26.4565. Epub 2019 Apr 1.
8
Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.复发/难治性原发性纵隔大 B 细胞淋巴瘤：流行病学、治疗指南和真实世界治疗实践的结构化综述。
Expert Rev Hematol. 2020 Mar;13(3):275-287. doi: 10.1080/17474086.2020.1716725. Epub 2020 Jan 28.
9
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.真实世界环境中 B 细胞非霍奇金淋巴瘤患者的临床结局：来自血液肿瘤学拉丁美洲观察性注册研究的结果。
JCO Glob Oncol. 2022 Mar;8:e2100265. doi: 10.1200/GO.21.00265.
10
Malignant lymphoma in Eastern India: a retrospective analysis of 455 cases according to World Health Organisation classification.印度东部的恶性淋巴瘤：根据世界卫生组织分类对455例病例的回顾性分析
J Cancer Res Ther. 2014 Apr-Jun;10(2):354-8. doi: 10.4103/0973-1482.136639.
引用本文的文献
1
Association of Selective VDR Gene Polymorphisms with Diffuse Large B-Cell Lymphoma (DLBCL) in a South Indian Population.南印度人群中选择性维生素D受体（VDR）基因多态性与弥漫性大B细胞淋巴瘤（DLBCL）的关联
Asian Pac J Cancer Prev. 2025 May 1;26(5):1761-1766. doi: 10.31557/APJCP.2025.26.5.1761.
本文引用的文献
1
Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.用于B细胞淋巴瘤的利妥昔单抗生物类似药：来自印度的十年真实世界经验
Lancet Haematol. 2021 Aug;8(8):e548-e549. doi: 10.1016/S2352-3026(21)00212-X.
2
Clinico-Pathologic Profile and Treatment Outcomes of Patients with Diffuse Large B Cell Lymphoma Based on Cell of Origin Classification.基于细胞起源分类的弥漫性大B细胞淋巴瘤患者的临床病理特征及治疗结果
Indian J Hematol Blood Transfus. 2021 Apr;37(2):226-231. doi: 10.1007/s12288-020-01322-8. Epub 2020 Jul 27.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.《2020年癌症统计数据：来自印度国家癌症登记计划的报告》
JCO Glob Oncol. 2020 Jul;6:1063-1075. doi: 10.1200/GO.20.00122.
5
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.在弥漫性大B细胞淋巴瘤患者中比较DRL-利妥昔单抗与美罗华的随机、双盲、药代动力学等效性试验。
J Glob Oncol. 2019 Nov;5:1-13. doi: 10.1200/JGO.19.00248.
6
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.生物类似药利妥昔单抗Reditux™在弥漫性大B细胞淋巴瘤中的群体药代动力学
Cancer Chemother Pharmacol. 2016 Aug;78(2):353-9. doi: 10.1007/s00280-016-3083-x. Epub 2016 Jun 21.
7
Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution.成人霍奇金淋巴瘤的临床特征与转归：来自一家三级医疗机构的经验
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):255-60. doi: 10.4103/0971-5851.171550.
8
Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India.淋巴瘤的组织病理学模式以及弥漫性大B细胞淋巴瘤的临床表现和预后：一项基于印度多中心登记处的研究
Indian J Med Paediatr Oncol. 2013 Oct;34(4):299-304. doi: 10.4103/0971-5851.125250.
9
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis.利妥昔单抗（美罗华™）及其生物类似药（利妥昔单抗生物类似药™）在接受化疗免疫治疗的弥漫性大B细胞淋巴瘤患者中的疗效和安全性比较：一项回顾性分析。
Indian J Med Paediatr Oncol. 2013 Oct;34(4):292-8. doi: 10.4103/0971-5851.125248.
10
Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer center in North India.霍奇金淋巴瘤——长期预后：印度北部一家三级癌症中心的经验。
Ann Hematol. 2011 Oct;90(10):1153-60. doi: 10.1007/s00277-011-1262-8. Epub 2011 May 28.
Zotero 插件